Shopping cart
Your cart empty!
'Game-changing' HIV prevention jab to be approved for use in England and Wales
A "game-changing" HIV-prevention treatment is set to be approved for use in England and Wales.
Cabotegravir (CAB-LA) is an injection administered every two months to reduce the risk of infection in HIV-negative adults and young people, offering an alternative to the daily pills that are used. The tablets, known as PrEP (pre-exposure prophylaxis), cannot be taken by some of those at risk because of medical or other reasons.
The National Institute for Health and Care Excellence (Nice) recommended CAB-LA for use in draft guidance published on Friday. CAB-LA is the first injectable PrEP option and the first PrEP medicine that Nice has approved.
It is expected to be available around three months after Nice publishes its final guidance later this year. Health Secretary Wes Streeting said the approval of the injection was "game-changing".
For vulnerable people unable to take other methods of HIV prevention, the injection "represents hope.
Amir Nisi
Creative and experienced content writer with 6+ years of experience lazy to create unique content strategy for News5 to turn website visitors into customers.
Related to this topic:
AI and Marketing: Unlocking Customer Insights
Feb 22, 2024
